Strategic and operational restructuring of a French CRO specialized in preclinical oncology research, in a context of deep market transformation. Major technological diversification toward next-generation methodologies (NAMs — New Approach Methodologies): advanced in vitro models, 3D bioprinting, and in silico models, aligned with evolving international regulatory frameworks (FDA Modernization Act 2.0, European guidelines) and biopharmaceutical industry expectations. Scope of intervention: — Strategic leadership: defining and deploying the strategic roadmap, repositioning the company along the value chain, with direct reporting to the chairman and shareholders. — Development of new high value-added services: design of a hybrid offering combining in vivo and NAMs approaches (3D bioprinted models and in silico models). — Innovation funding strategy: structuring and securing a portfolio of R&D projects (SATT, France 2030, Eurostars) representing a combined budget of €700K. — Strategic partnerships: developing academic and industrial collaborations supporting the deployment of the NAMs offering. — Commercial and marketing structuring: overhaul of the commercial strategy.

Part-time Chief Operating Officer of a London-based Biotech startup developing and bringing to market a proprietary regenerative cosmetic treatment, in partnership with the cell therapy laboratory of AP-HM (Assistance Publique — Hôpitaux de Marseille). Scope of intervention: — R&D leadership: defining the scientific-industrial specifications and supervising outsourced R&D conducted with the academic partner, including the development and validation of a proprietary protocol. — Market access strategy and design-to-cost approach: significant reduction of the market acccess cost and funding need — Operations structuring: modeling core processes, selecting and deploying a SaaS platform coordinating internal activities, clients, clinical and logistics partners. — Supply chain and operational infrastructure: end-to-end supply chain design (clinical procurement, transport, processing, storage, distribution), selection of key suppliers, supervision of laboratory setup, and recruitment of its lead. — Investor relations: contribution to the fund raising process leading to £1M to be raised for R&D, industrialization, and market access.

Operating Partner to executives, boards, and investment funds in Biotech, Medtech, and Deep Tech. Types of engagements: — Fractional executive mandates: Fractional CEO or COO roles with SMEs and startups in phases of structuring, growth, or strategic transformation. — Innovation project qualification and validation: strategic diagnosis, assessment of technological, industrial, and market maturity (TRL/MRL/RRL), value proposition design. — Market access: end-to-end path design from prototype to market, commercialization strategy, structuring of clinical and industrial partnerships. — Innovation funding strategy: identification and mobilization of public funding (SATT, France 2030, Eurostars, Bpifrance) and private fund raising, structuring of academic and industrial consortia. — Executive and board advisory: supporting founders and executives on their major strategic challenges (fundraising, pivots, international go-to-market). Assignments in France and internationally. Availability of 1 to 3 days per week depending on the scope.

Manutech USD is Europe's first platform dedicated to industrial applications of femtosecond laser technology, a breakthrough technology for surface treatment and precision manufacturing. Equipex (Equipment of Excellence) and public-private economic interest group (GIE) bringing together academic and industrial stakeholders. Design and leadership of a French Tech–accredited technology transfer program, aimed at identifying, qualifying, and validating high-value industrial applications of an emerging deep tech technology. Scope of intervention: — Program architecture: development of a consulting offering co-funded by Saint-Étienne Métropole and regional partners, enabling startups, SMEs to identify high-value applications and conduct proof-of-concept studies (product or process innovation). — Multi-sector strategic prospecting: 400 projects identified and 100 projects audited across a cross-industry spectrum (consumer goods, aeronautics, aerospace, medical, robotics, cultural industries). — Business development and client portfolio: structuring a strategic industrial client base for the GIE, with 40 new client accounts opened with emerging companies or leading French companies in diagnostics, cosmetics, medical devices, and industrial manufacturing. — Industrial feasibility studies: 40 sector-specific studies enabling clients to qualify the potential of the technology for their target applications, from proof-of-concept to industrialization projections. — Research-industry interface: orchestrating the relationship between the Equipex's academic laboratories and the R&D and industrial leadership of client companies.

Co-founder and Co-CEO of Anastom Surgical, a medtech startup developing a proprietary automated circular suturing technology, initially applied to oncological surgery (prostate cancer). Scope of intervention: — Strategy and company structuring: co-building the business case, market study, customer segmentation, business plan, and strategic positioning. — Financial engineering and fundraising: structuring public and private financing, building research consortia, securing a €1.5M budget over 4 years, allowing the company to bring the project from the concept stage to successful in vivo validation preclinical trials. — Intellectual property: structuring and filing 3 international patents protecting the proprietary technology. — Scientific and medical development: building an international advisory board composed of KOLs from leading surgical centers (Cleveland Clinic, Johns Hopkins, Lyon, New York).